The Role of Tpl2 Protein Kinase in Carcinogenesis and Inflammation by Katie DeCicco-Skinner et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
3 
The Role of Tpl2 Protein Kinase  
in Carcinogenesis and Inflammation 
Katie DeCicco-Skinner1, Monika Deshpande2 and Jonathan Wiest2  
1Department of Biology, American University, Washington, DC, 
 2Laboratory of Cancer Biology and Genetics,  
National Cancer Institute,  
National Institutes of Health, Bethesda, MD  
USA 
1. Introduction 
The mitogen activated protein kinase (MAPK) cascade is a family of serine-threonine 
protein kinases controlling a vast array of cellular responses. Among the oldest signaling 
pathways known, the MAPK cascade is evolutionarily conserved, being found in species 
ranging from yeast to humans (Widmann et al., 1999). All eukaryotic cells possess multiple 
MAPK signaling pathways. In mammals, four major subfamilies (termed classical MAPKs) 
have been identified including extracellular signal-regulated kinase 1/2 (ERK1/2), c-jun N-
terminal protein kinases (JNK/SAPK), p38 isoforms (p38 , , , or ), and ERK5 
(Dhanasekaran and Johnson, 2007). These multiple parallel MAPK cascades all operate 
through a three tiered system characterized by consecutive phosphorylation events. Each of 
the pathways is equipped to respond to a remarkably diverse array of stimuli, including 
cytokines, growth factors, irradiation, hormones, injury, and stress (Cargnello and Roux, 
2011). The binding of stimuli to receptors triggers the initial phosphorylation events. These 
events transform inactive MAP3K into active MAP3K. Subsequently, active MAP3K 
phosphorylates, and thereby activates, downstream MAP2K (MEK) proteins. The active 
MAP2K proteins then phosphorylate MAPK (ERK) molecules. These MAPK proteins then 
regulate the transcription of a diverse group of genes involved in inflammation, cell 
survival, cell division, development, metabolism, differentiation, motility, and repair 
(Cargnello and Roux, 2011).  
Additionally, over the last two decades atypical pathways including ERK 3/4, ERK 7/8 and 
Nemo-like kinase (NLK) have been discovered (Cargnello and Roux, 2011). Similar to 
classical MAPK family members, these proteins phosphorylate target substrates on serine or 
threonine residues. However, they are not organized into the classical three-tiered model 
and contain a less well conserved motif on the activation loop of the kinase domain.  
Due to the diverse effects that MAPK signaling pathways have on cellular processes, the 
classical MAPK pathways have been intensely studied to assess their role in human disease. 
Detailed reviews for each pathway were previously published (Weston and Davis, 2007; 
Wagner and Nebreda, 2009; Cargnello and Roux, 2011; Schindler et al, 2007; Nishimoto and 
Nishida, 2006). Therefore, this chapter will focus on one protein kinase, Tpl2, within the 
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MAPK family and how altered expression (either underexpression or overexpression) of this 
kinase is linked to inflammation, cancer and other disease states.  
2. The MAP3K8/Tpl2 gene 
MAP3K8 (known as Cot or Tpl2 in rodents) is a MAP3K protein first isolated from thyroid 
tumors as a gene capable of inducing morphological transformation of NIH3T3 and SHOK 
cells (Miyoshi et al., 1991). Structurally, the open reading frame of the Tpl2 gene encodes a 
467 amino acid polypeptide (Aoki et al., 1991). Provirus integration occurring in the last 
intron of the Tpl2 gene in rodents generates a mutant protein 36 amino acids shorter than 
the full length version and also is an activating mutation (Patriotis et al., 1993; Erny et al., 
1996; Ceci et al., 1997). This truncated Tpl2 gene has enhanced kinase activity (Gandara et al., 
2003). Additionally, analysis of the N-terminal region of this gene reveals three alternate 
translation start sites. Consequently, the polypeptides translated from the Tpl2 gene will 
contain 467, 464, or 438 amino acids (Aoki et al., 1991). The 467- and the 464-amino acid 
proteins are detected as a single 58-kDa band by Western Blot analysis and the 438 amino 
acid protein is detected as a 52-kDa band.  
Functionally, some differences exist between these two forms of the protein. The 58-kDa 
protein has a shorter half-life (10 minutes) than the 52-kDa protein (30 minutes). Thus, the 
amino-terminal domain contains sequences important for Tpl2 stability. Additionally, cell 
lines transformed with constructs only expressing the 58-kDa Tpl2 protein have higher 
tumor incidence and reduced latency when compared to cell lines transformed with the 52-
kDa protein indicating that the N-terminal region of the protein is important in regulating 
function of this gene (Aoki et al., 1991).  
Tpl2 has the ability to cross-talk with numerous signaling pathways. In unstimulated cells 
Tpl2 forms a ternary complex with Nuclear factor kappa B p105 (NF-B p105) and A20-
binding inhibitor of NF-B2 (ABIN-2) (Lang et al., 2004). This complex increases Tpl2 stability 
and renders Tpl2 inactive towards its main downstream substrate MEK, the ERK kinase. Upon 
activation by inflammatory stimuli, Tpl2 becomes phosphorylated by B kinase (, 
releasing both Tpl2 and NF-B to participate in downstream signaling. In addition to 
participating in ERK signaling, Tpl2 can cross-talk with multiple MAPK signaling pathways 
including p38, JNK, ERK 1/2, and ERK 5 (Salmeron et al., 1996, Patriotis et al., 1993, Chiariello 
et al., 2000) (Figure 1). Additionally, wildtype and mutant Tpl2 activates the transcription 
factor NFAT in response to stimulation through the T cell receptor (TCR) and causes 
heightened activation of NF-B (Tsatsanis et al., 1998, Belich et al., 1999).  
3. Tpl2 regulation involves NF-B 
Our understanding of Tpl2 regulation was greatly enhanced by the identification of the 
interaction between p105 and Tpl2 (Belich et al., 1999). p105 is a NF-B precursor protein 
which also acts as a NF-B-inhibitory protein by sequestering NF-B complexes in the 
cytoplasm of cells (Rice et al., 1992). Stoichiometric binding of Tpl2 to the C-terminus of p105 
occurs within two distinct regions of Tpl2. The C–terminal region of Tpl2 (residues 398-467) 
binds to a region adjacent to the ankyrin repeats on p105 (residues 497 to 534), while the kinase 
domain of Tpl2 binds to the death domain on p105 (Beinke et al., 2003). In steady state 
conditions, the entire pool of Tpl2 is associated with p105, irrespective of the cell type, whereas 
only about one third of the p105 pool is occupied by binding to Tpl2 (Belich, et al., 1999).  
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Fig. 1. Tpl2 signaling pathways. Tpl2 interacts with numerous signaling pathways including 
ERK, JNK, p38, and NF-B. Tpl2 is normally held in complex with Abin-2 and p105. Upon 
activation with a stimulus, IKK phosphorylates p105, freeing Tpl2 to participate in ERK, JNK 
and p38 signaling and p50 to heterodimerize with other NF-B family members. 
Functionally, this interaction between Tpl2 and p105 is significant. p105 binding to Tpl2 
inhibits Tpl2 kinase activity and thus prevents Tpl2 from being able to activate downstream 
signaling cascades. Despite this ability to inhibit Tpl2 kinase activity, p105 improves Tpl2 
solubility and stability (Beinke, et al., 2003; Jia, et al., 2005). Tpl2, when not bound to p105, is 
unstable, appears to have difficulty folding and can form insoluble aggregates (Jia, et al., 
2005). Despite the fact that Tpl2 binds p105, p105 is not necessary for Tpl2 gene expression. 
Bone-marrow derived macrophages (BMDMs) and splenocytes that lack p105 have normal 
Tpl2 gene expression levels (Waterfield, et al., 2003). However, Tpl2 protein levels in these 
cells are significantly reduced. This reduction in Tpl2 protein expression is correlated with a 
subsequent reduction in LPS induced ERK signaling (Waterfield et al., 2003). This indicates 
that binding to p105 not only confers Tpl2 stability, but it also renders it unable to 
phosphorylate MEK, possibly by blocking access to MEK (Waterfield et al., 2003; Bienke et 
al., 2003). The inactivity of Tpl2 in the complex may function as a mechanism to prevent 
unregulated Tpl2 activity in unstimulated cells.  
As discussed later in this chapter, truncation of Tpl2 in its C-terminus greatly enhances the 
catalytic activity and oncogenic potential of Tpl2 in T cell lymphomas (Ceci, et al., 1997). Since 
the interaction of Tpl2 with p105 requires the C terminus of Tpl2 in vitro, truncation of Tpl2 
could theoretically change the association between Tpl2 and p105. In 2003, Beinke addressed 
this issue and found that truncation of Tpl2 did not hinder the ability of this protein to bind 
to p105 (Beinke, et al., 2003). However, it did block the ability of p105 to negatively regulate 
Tpl2 kinase activity. The heightened Tpl2 kinase activity found in Tpl2 truncated cells can 
result in persistent phosphorylation of targets such as MEK, ultimately leading to increased 
gene expression of numerous genes involved in cell cycle progression (Matsumura, et al., 
2009). Additionally, increased Tpl2 kinase activity can be oncogenic, as aberrant MEK/ERK 
activity has been identified in several cancer types (Matsumura, et al., 2008).  
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In 2004, a third protein, ABIN-2, was reported to associate with the Tpl2/p105 complex 
(Lang, et al., 2004). Tpl2 and ABIN-2 bind to similar regions on the C-terminal region of 
p105. Both Tpl2 and ABIN-2 bind to the death domain and bind to residues 497-538. 
However, ABIN-2 also needs to bind to the PEST region of p105 for optimal association. It is 
reported that in order to maintain steady state protein levels of Tpl2, ABIN-2 is necessary 
(Lang, et al., 2004). However, it is not involved in maintaining protein levels of p105. 
Whereas, the functional significance of the role of ABIN-2 in the Tpl2/p105 complex has not 
been fully elucidated, it has been shown that the solubility of ABIN-2 is increased by 
binding to p105. Therefore, similar to what was described above for Tpl2, it appears that 
ABIN-2 binding to p105 is required to ensure correct protein folding.  
Tpl2 is activated in response to various proinflammatory stimuli such as lipopolysaccharide 
(LPS), tumor necrosis factor (TNF) and CD40 ligand. LPS stimulation results in IKK-induced 
p105 proteolysis, releases Tpl2 from p105, renders Tpl2 enzymatically active, and increases 
downstream MEK kinase activity (Beinke et al., 2004; Waterfield et al., 2003). This newly 
liberated Tpl2, which is now susceptible to rapid degradation by the proteosome, will 
phosphorylate substrates in the ERK and JNK pathways. Additionally, p105 is subsequently 
degraded into p50 by the proteosome (Beinke, et al., 2004). The p50 subunit can now 
dimerize with other NF-B family members and translocate to the nucleus where the active 
NF-B complex can regulate over 400 genes. The overall result is an upregulation of diverse 
genes involved in growth, differentiation, and inflammation.  
4. Tpl2 knockout mice 
Despite the significant function Tpl2 has in eliciting cellular responses, Tpl2-/- animals 
appear phenotypically normal (Dumitru et al., 2000). Immune organs including bone 
marrow, thymus, spleen, and lymph nodes all develop normally and production of T and B 
cell subsets are unaltered. Additionally, when subjected to challenge by T cell-dependent 
and independent antigens such as KLH and LPS-TNP, Tpl2-/- mice produce normal 
antibody responses (Dumitru et al., 2000).  
Over the last decade, numerous laboratories have used a variety of disease models to assess 
the response of Tpl2-/- mice to bacterial, viral, or carcinogenic challenge. However, the 
results have shown differential responses to challenge, with the absence of Tpl2 sometimes 
promoting a disease state and sometimes protective against the disease. These differing 
responses are most likely due to variation in stimuli used and is cell-type specific. As 
described below, most laboratories have used lipopolysaccharide (LPS), which binds 
through TLR4, as the major stimulus in Tpl2-/- mice. However, targeting different receptors 
through the use of other stimulators such as 12-O-tetradecanoylphorbol-13-acetate (TPA), 
Poly IC, or CpG receptors can yield different responses. Thus, because Tpl2 can signal 
through numerous pathways, analysis of the effects of underexpression or overexpression of 
this protein kinase is quite convoluted. 
4.1 Evidence supporting that Tpl2
-/-
 mice exhibit lower levels of inflammatory markers  
Several laboratories have reported a reduction in pro-inflammatory cytokines in Tpl2-/- 
mice. Dumitru reported that TNF- is markedly lower in Tpl2-/- macrophages stimulated 
with LPS, providing Tpl2-/- mice with resistance to LPS/D-Galactosamine stimulated 
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endotoxic shock (Dumitru et al., 2000). Others have reported similar findings, deficits in 
TNF-, Cox-2, PGE2, and CXCL1 in LPS-stimulated macrophages (Eliopoulos et al., 2002; 
López-Peláez et al., 2011). In LPS-stimulated Tpl2-/- macrophages, this impaired secretion of 
TNF- and PGE2 is triggered by a defect in ERK activation. Additionally, in bone marrow-
derived dendritic cells (BMDCs) and macrophages, Tpl2-/- mice have significantly lower 
expression of IL-1 in response to LPS, poly IC and LPS/MDP (Mielke et al., 2009). 
Consequently, these mice displayed significantly higher mortality and bacterial burden 
when infected with L. monocytogenes. Recently, it was reported that obese Tpl2-/- mice have a 
significant reduction in TNF- and monocyte chemoattractant protein-1 (MCP-1) in adipose 
tissue compared to WT controls (Perfield, et al., 2011). This reduction in inflammatory 
markers in Tpl2-/- mice was associated with an improvement in whole-body insulin 
resistance. Because inhibition of Tpl2 is associated with a reduction in inflammatory markers 
in LPS-stimulated cells, several pharmaceutical companies have developed small molecule 
inhibitors of Tpl2 to assess whether inhibition of this protein can be beneficial for chronic 
inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease, and 
pancreatitis. Details on these studies are outlined later in this chapter. 
4.2 Tpl2
-/-
 mice can display enhanced pro-inflammatory profiles 
Contradictory to the details above, our laboratory and others have reported heightened 
inflammatory responses in Tpl2-/- mice. López-Peláez found that Tpl2 deficiency in LPS-
stimulated macrophages was associated with an increase in Nitric Oxide Synthase 2 
expression (López-Peláez et al., 2011). Similarly, Zacharioudaki found that expression of 
IRAK-M, whose function is to compete with IL-1R-associated kinase (IRAK) family of 
kinases, is decreased in Tpl2-/- macrophages (Zacharioudaki et al.,  2009). This deficit in 
IRAK-M in Tpl2-/- macrophages was associated with elevations in TNF and IL-6 and a 
hyperresponsiveness to LPS. 
Our laboratory examined the inflammatory response in TPA-treated Tpl2-/- or wild type 
mouse skin (DeCicco-Skinner, et al., 2011). We found significantly higher numbers of 
neutrophils in Tpl2-/- mice, achieving levels 35 times greater than control animals within 12 
hours (DeCicco-Skinner et al., 2011). Additionally, the skin of Tpl2-/- mice exhibited 
significant increases in the number of mast cells, CD3+ cells and the pro-inflammatory 
cytokines IL-12 and IL-1 .  
The heightened inflammation found in the skin of Tpl2-/- mice may be initiated by aberrant 
inflammatory signaling pathways. Numerous inflammatory pathways are associated with 
Tpl2 activity including ERK, JNK, p38 and NF-B. We used selective inhibitors specific to 
each of these pathways both in vitro and in vivo to assess differential responses in 
keratinocytes from Tpl2-/- or wildtype mice and found that a dysregulation in NF-B 
activation and signaling is the primary defect in Tpl2-/- keratinocytes (DeCicco-Skinner, et 
al., 2011). We confirmed that keratinocytes from Tpl2-/- mice have basal and TPA-treated 
NF-B activity levels significantly greater than wildtype mice using an NF-B reporter 
assay. Moreover, whereas treatment with an NF-B inhibitor could block edema and 
neutrophil infiltration in wildtype mice, the inhibitor was unable to block the exaggerated 
NF-B response in the Tpl2-/- mice. Additionally, using confocal microscopy we found high 
levels of active p65 NF-B present in the nucleus of Tpl2-/- keratinocytes prior to TPA 
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treatment that dramatically increased within 15-30 minutes of TPA treatment. The increase 
in active NF-B may be explained by lower levels of inhibitory proteins that normally 
sequester NF-B in the cytoplasm of cells. In this regard we found that wildtype mice had 
significantly higher protein levels of the NF-B inhibitors IB alpha and IB beta compared 
to Tpl2-/- animals. Others have reported similar findings as our laboratory (Mielke et al., 
2009; López-Peláez et al., 2011). Mielke reported that Tpl2-/- bone marrow-derived dendritic 
cells (BMDCs) displayed increased p65 NF-B both basally and after stimulation with LPS 
when compared to wildtype controls (Mielke, et al., 2009). Similarly, they found that 
increased IB degradation may be partially responsible for the heightened NF-B levels. 
Moreover, López-Peláez demonstrated that while degradation of the NF-B inhibitor IB 
alpha was similar between Tpl2-/- and wildtype BMDMs, Tpl2-/- cells exhibited a slower 
recovery in IB alpha protein levels, remaining low at 4 hours post LPS treatment (López-
Peláez et al., 2011).  
The data associating the absence of Tpl2 with a heightened NF-B activation, opposes what 
others have found. Previous reports have shown LPS stimulation leads to equal induction of 
NF-B in Tpl2-/- and control macrophages (Dumitru et al., 2000). Others have shown that 
Tpl2-/- mouse embryo fibroblasts and Jurkat T cells with kinase-deficient Tpl2 have a 
reduction in NF-B activation but only when certain stimuli are administered (Lin et al., 
1999; Das et al., 2005). Thus the relationship between Tpl2 and NF-B still remains an 
enigma and more work is needed to clarify the nuances of this interaction.  
It is possible that whether Tpl2 serves more of a pro-inflammatory or anti-inflammatory role 
may depend on cell type and stimuli. As previously mentioned, Tpl2 exhibits broad 
specificity because it interacts with numerous signaling pathways. Most of the previous 
reports that found Tpl2 to be proinflammatory used stimuli functioning through TLRs. It 
should be noted that the two stage skin carcinogenesis model used in our model employs 
TPA as a tumor promoter signaling through protein kinase C (PKC). PKC is a multigene 
family of serine/threonine kinases (Griner and Kazanietz, 2007). Six isoforms of PKC are 
expressed in mouse keratinocytes, namely,  (Reddig et al., 1999). Each isoform 
contributes differently to normal keratinocyte growth and differentiation, and, if 
inappropriately regulated, certain isoforms are associated with disease pathogenesis. It is 
currently unknown if one or more PKC isoforms are dysregulated in Tpl2-/- mice.  
4.3 Tpl2
-/-
 mice have alterations in T cell polarization 
Tpl2 is reportedly activated in rodents by provirus integration in retrovirus-induced T cell 
lymphomas (Ceci et al., 1997). Therefore, due to this connection with T cells, several 
laboratories have investigated if Tpl2-/- mice have alterations in T cell profiles in response to 
antigenic challenge. Watford, et al. reported that Tpl2 was induced by IL-12 in human and 
mouse T cells in a Stat4-dependent manner (Watford et al., 2008). Tpl2-/- mice have impaired 
host defense against Toxoplasma gondii, reduced parasite clearance, and decreased IFN- 
production. Additionally, ovalbumin-immunized Tpl2−/− mice challenged with ovalbumin 
developed more severe bronchoalveolar eosinophilic inflammation than wildtype controls 
(Watford et al., 2010). Tpl2−/− mice were polarized toward a Th2 response, exhibiting 
heightened IL-4 and IL-10 signaling. In contrast, Sugimoto, et al. reported a significant 
increase in IL-12 and a decrease in CpG-DNA treated Tpl2-/- macrophages and dendritic 
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cells, polarizing the mice toward a Th1 profile (Sugimoto et al., 2004). Additionally, it has 
been reported that IL-23, a cytokine necessary for expansion and stabilization of Th17 cells, 
is reduced in Tpl2-/- macrophages indicating Tpl2 may be involved in balancing Th1/Th17 
differentiation (Kakimoto, et al., 2010).  
5. Tpl2 and carcinogenesis 
The exact role of Tpl2 in carcinogenesis is also convoluted. Early reports demonstrated Tpl2 
truncation of the C-terminus, resulting from provirus insertion, to be associated with T-cell 
lymphoma (Ceci et al., 1997). Additionally, overexpressing the truncated form of this gene 
was associated with rodent T-cell lymphomas and an accelerated cell cycle in T 
lymphocytes.  
Subsequently, several reports found elevated MAP3K8 activity in a number of human 
cancers including breast, endometrial, thymomas, lymphomas, lung, Hodgkin’s disease, and 
nasopharyngeal carcinoma (Salmeron et al., 1996; Sourvinos et al., 1999; Patriotis et al., 1993,; 
Tsatsanis et al., 2000; Eliopoulos et al., 2002; Clark et al., 2004). In lymphomas the enhanced 
MAP3K8 activity could modulate ERK1/2 effector proteins such as p70 S6K and Jun B, 
resulting in an increased progression through the cell cycle (López-Peláez et al., 2011; 
Fernández et al., 2011). Recently it was reported that overexpression of Tpl2 induced 
androgen-dependent prostate cancer growth, and that MAP3K8 was upregulated in prostate 
cancers in mouse models and clinical specimens (Jeong et al., 2011). Additionally, 
heightened MAP3K8 expression levels are correlated with acquired resistance to drug 
therapy in melanoma (Johannessen et al., 2010). The physiological role of Tpl2 in the etiology 
of human cancers remains a mystery. Overexpression of Tpl2/MAP3K8 in vivo is weakly 
oncogenic and Tpl2/MAP3K8 mutations in human cancers are rarely found (Ceci et al., 1997; 
Clark et al. 2004, Vougioukalaki et al., 2011). 
In contrast to the oncogenic role of Tpl2, recent evidence suggests that under certain 
conditions Tpl2 may serve a tumor suppressor role. Using Tpl2-/- mice crossed with the T 
cell receptor transgene, Tsatsanis found that 81% of mice developed T cell lymphomas 
within 6 months whereas lymphomas were absent from wildtype mice (Tsatsanis et al., 
2008). This heightened carcinogenesis was due to chronic stimulation of splenic T cells in 
Tpl2-/- mice, for anti-CD3/anti-CD28 stimulated Tpl2-/- splenocytes have increased 
proliferation and reduced expression of a negative regulator of T cell activation, CTLA4 .  
Moreover, our laboratory recently reported that Tpl2 can act as a tumor suppressor gene in 
chemically-induced skin cancer (DeCicco-Skinner et al., 2011). In our model, Tpl2-/- or 
wildtype mice were subjected to a two-stage dimethylbenzanthracene/ 12-O-
tetradecanoylphorbol-13-acetate (TPA) mouse skin carcinogenesis model. We found that 
Tpl2-/- mice developed a significantly higher incidence of tumors (80%) than wildtype mice 
(17%), as well as reduced tumor latency and a significantly higher number of total tumors 
(113 vs 6). Additionally, keratinocytes from Tpl2-/- mice were found to have an accelerated 
cell cycle as demonstrated in vivo through heightened Ki67 staining.  
A skin grafting protocol has been used by our laboratory to further determine the in vivo 
phenotype of keratinocytes and fibroblasts from Tpl2-/- and wildtype mice. In agreement 
with our two-stage skin carcinogenesis model, we found that nude mice grafted with 
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fibroblasts and v-rasHa -transduced keratinocytes from Tpl2-/- mice developed tumors nine 
times larger than mice grafted with fibroblasts and v-rasHa -transduced keratinocytes from 
wildtype mice. Additionally, mice grafted with mixed genotypes (WT fibroblasts/KO 
keratinocytes or KO fibroblasts/WT keratinocytes) developed tumors that were 
intermediate in size suggesting a defect in Tpl2 signaling in both fibroblasts and 
keratinocytes was responsible for the increased tumor formation. 
Despite the fact that Tpl2 can serve as an oncogene, and sometimes a tumor suppressor gene 
in mice and rats, the physiological response of Tpl2 in the etiology of human cancers 
remains a mystery. Our laboratory has previously identified a Tpl2 truncation mutant in a 
primary human lung adenocarcinoma, but analyses of other lung cancers suggest this isn’t a 
common occurrence (Clark et al., 2004). Additionally, others have searched the Sanger 
Institute COSMIC database for Tpl2 gene mutations and identified only one human tumor 
sample (out of 477) that contained a point mutation in the Tpl2 gene (Gantke et al., 2011; 
Parsons et al, 2008). The significance of this point mutation in the development or 
progression of the patient’s glioblastoma multiforme is unknown.  
6. Tpl2 inhibitors 
As described above, Tpl2 can interact with several inflammatory pathways. It activates the 
MEK/ERK pathway and plays a pivotal role in the production and signaling of TNF. Tpl2 
also regulates TNF-R signaling and the production of type 1 interferon and other pro-
inflammatory cytokines such as IL-1. In macrophages stimulated by LPS, Tpl2 activates the 
MAPK pathway. Overexpression of Tpl2 activates the MAPK signaling pathways, NFAT, 
and induces IL-2 production which further activates NF-B via the NF-B inducing kinase 
(NIK) (Patriotis et al., 1994; Salmeron et al., 1996; Tsatsanis et al., 1998a and 1998b; Lin et al, 
1999). Analysis of Tpl2-/- mice revealed a role for Tpl2 in TLR, IL-1, CD40, TCR, and also 
reduction of LPS-induced TNF- production (Dumitru et al., 2000; Tsatsanis et al., 2008; 
Eliopoulos et al., 2003). TNF-, a pro-inflammatory cytokine, is involved in the initiation and 
progression of inflammatory diseases such as rheumatoid arthritis (RA), psoriasis, 
inflammatory bowel disease, and multiple sclerosis (Feldmann et al., 2005). TNF-also 
stimulates the production of other proinflammatory cytokines such as interleukin-1 (IL-1) 
and interleukin- 6 (IL-6), and induces the activity of enzymes such as the matrix 
metalloproteases (MMPs), all of which contribute to RA. Inhibition of TNF- with a number 
of biological agents that bind and neutralize TNF-has offered a significant therapeutic 
advantage in treating RA (Jarvis & Faulds, 1999,; Elliot et al., 2008; Bang & Keating, 2004). 
The therapeutics included soluble TNF receptor and monoclonal antibodies for the 
neutralization of TNF-, such as etanercept (soluble TNFRII-Fc; Enbrel), infliximab 
(Remicade), and adalimumab (anti-TNF antibodies; Humira) and have improved the 
quality of life of RA patients.  
The success of these drugs has validated the use of anti-TNF- therapies for treating 
arthritic and inflammatory diseases. It has also necessitated the search for additional small 
molecule inhibitors with similar or related mechanisms of action. Major pharmaceutical 
companies have focused on the inhibition of TNF-production through either inhibiting 
TNF- converting enzyme or the disruption of signal transduction pathways that include 
several members of the MAPK family. However, the therapeutic agents described above 
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require administration via injection or infusion. Therefore, identification of an orally 
available small molecule therapy would provide an additional benefit to patients. Since Tpl2 
inhibition can decrease TNF-levels, it has become an attractive target for treating RA and 
an orally available small molecule inhibiting TNF- synthesis and/or signaling could have 
widespread therapeutic potential. Since Tpl2 ablation protects mice from TNF- -induced 
inflammatory bowel disease and pancreatic and pulmonary inflammation, Tpl2 inhibition is 
an attractive strategy for treating these diseases.  
Research studying the effect of Tpl2 inhibition on disease outcome is still in its infancy 
because only a handful of small molecule inhibitors of Tpl2 have been identified. A few 
factors contribute to the paucity of Tpl2 inhibitors. First, no crystal structure is available for 
Tpl2. Second, Tpl2 has low homology to other kinases. Although this is an advantage in 
selecting unique targets, it also presents significant challenges for structure-based drug 
design, especially when coupled with the lack of crystal structure. On the other hand, Tpl2 
is not inhibited by staurosporine, a nonspecific kinase inhibitor, and it is the only known 
human kinase that has a proline instead of a conserved glycine in the glycine-rich ATP 
binding loop (Luciano et al., 2004; Patriotis, et al., 2003). These factors may lead to the 
discovery of highly selective inhibitors. Nonetheless, several strategies have been used to 
synthesize and/or isolate Tpl2 inhibitors. 
One natural product inhibitor of Tpl2 has been identified. Luteolin [2-(3,4-dihydroxyphenyl)-
5,7-dihydroxy-4-chromenone] is a flavonoid found abundantly in green peppers, perilla, 
celery, and chamomile tea. Luteolin has been shown to inhibit TNF--induced COX-2 
expression in mouse skin epidermal cells by inhibiting Tpl2 activity (Kim et al., 2011).  
Several synthetic inhibitors of Tpl2 have also been characterized with 1,7-Naphthyridine-3-
carbonitriles 1 and quinoline- 3-carbonitrile 2 as the earliest classes of compounds reported 
as reversible and ATP-competitive Tpl2 kinase inhibitors. These Tpl2 inhibitors demonstrate 
a good correlation between cell free Tpl2 inhibition with p-MEK and TNF inhibition in cell-
based assays. Thieno [2,3-c]pyridines and pyrimidines are the other two classes of Tpl2 
inhibitors studied recently. 1,7-napthyridine- 3-carbonitriles and quinoline-3-carbonitriles, 
indazoles, and thienopyridines are the most common Tpl2 inhibitors. These classes of 
compounds will be discussed below.  
Gavrin et al., (2005) first described a series of 6-substituted-4-anilino-[1,7]-naphthyridine-3-
carbonitriles as Tpl2 inhibitors evaluated in cell-free, cellular, and blood environments. One 
of these compounds, 1,7-naphtyridine- 3-carbonitrile, was used successfully to inhibit 
RANKL-induced osteogenesis through the induction of transcription factors c-Fos and 
NFATc1 in RANKL treated cells, unraveling the pivotal role played by Tpl2 in 
osteoclastogenesis (Hirata et al., 2010). The same inhibitor subsequently demonstrated that 
LPS-induced TNF- production via the Tpl2-MEK signaling is regulated by modulating the 
levels of tip-associated protein (Hirata et al., 2010a). It appears that Tpl2 might be involved 
in not only the post-transcriptional but also the translational stages of TNF- production. 
Some of the carbonitriles were further tested in primary human monocytes and blood. 
Inhibition of Tpl2 led to a decrease in production of TNF- and other pro-inflammatory 
factors. In synoviocytes, the inhibitors blocked ERK activation, COX-2 expression, and the 
production of IL-6, IL-8, PGE2, MMP-1 and MMP-3, further validating the role of these 
inhibitors as therapeutics (Hall et al., 2007).  
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A series of quinoline-3-carbonitriles were synthesized and tested in cell-based 
phosphorylation assays in LPS-treated human monocytes. Compounds were identified that 
selectively inhibited pMEK formation and LPS/D-Gal-induced TNF-α release (Hu et al., 
2006). Another series of compound synthesis involved studying 8-chloro-4-(3-chloro-4-
fluorophenylamino)-6-((1-(1-ethylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)methylamino)quinoline-
3-carbonitriles that inhibited TNF- production in an LPS-stimulated rat inflammation model. 
This was an important step in Tpl2 inhibitor identification since this compound was orally 
efficacious and demonstrated potential for oral treatment for RA (Wu et al., 2009). 
Structure based design efforts yielded a series of novel Indazole-based compounds. These 
compounds showed promising results as Tpl2 inhibitors as tested in LANCE based and cell-
based pERK assays. Some of the top compounds inhibited pERK activity in monocytes and 
had an IC50 of 3.2M. They exhibited good kinase selectivity against certain kinases but not 
against others. Efforts to improve their kinase selectivity profile are under way (Hu et al., 
2011).  
Another novel series of 7-amino substituted thieno[2,3-c]pyridines was identified as Tpl2  
inhibitors with an IC50 of 1M. These compounds were studied for their Tpl2 inhibition and 
selectivity against kinases. They successfully and selectively inhibited the Tpl2 pathway 
following LPS stimulation in macrophages and BMDM cells in a dose-dependent manner 
and showed good selectivity over MEK and ERK (Cusac et al., 2009). More recently, a high 
through-put screening of a compound library yielded thieno[3,2-d]pyrimidines as 
promising Tpl2 kinase inhibitors. They had an IC50 as low as 0.18 M, exhibited good 
binding to the Tpl2 protein as shown by biacore-based competitive binding studies, and 
showed good selectivity against kinases (Ni et al., 2011). 
7. Conclusion 
There has been an explosion of interest in Tpl2 inhibitors to treat RA and other 
inflammatory and autoimmune diseases. However, similar to the description above for the 
role of Tpl2 in carcinogenesis, it may be an oversimplification of the situation to assume that 
inhibition of Tpl2 would reduce inflammation. We have found thirty times higher 
neutrophil numbers in TPA-treated skin from Tpl2 knockout mice when compared to 
wildtype TPA-treated mouse skin. Additionally, we have found higher edema, 
inflammatory enzymes and cytokines in Tpl2 knockout mice (DeCicco-Skinner et al., 2011). 
Moreover, in contrast to the description above in RA-FLS cells, we have identified 
significantly elevated COX-2, PGE2 and PGE2 receptor levels in Tpl2 knockout keratinocytes 
with the elevated COX-2 contributing to increased skin tumorigenesis (unpublished 
findings).  
In summary, more research needs to be conducted to clarify the role that Tpl2 plays in 
immune responses, carcinogenesis, and inflammatory conditions. We caution that Tpl2 gene 
regulation needs to be better understood before inhibitors are used systemically. Tpl2 
appears to have divergent roles in different cells and tissues, and therefore drugs used to 
selectively inhibit Tpl2 in the hopes of controlling inflammation may actually exacerbate 
inflammation and carcinogenesis in certain tissues such as skin.  
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